Xolair 300 MG/2 ML syringe 2ML
Ended Awarded Last action
- Contract number
- SPE2DR26FSBF5
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $9,137
Award facts
- Contract value 100% obligated
- $9,136.50 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency issued a $9,136.50 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for 300 mg/2 mL syringes of Xolair. The award was made on January 27, 2026, with an ultimate completion date of February 18, 2026. This delivery order carries no set-aside designation, reflecting the contractor's competitive capability in unrestricted federal procurement. The contract represents a tactical pharmaceutical supply requirement supporting the Department of Defense's medical supply chain operations.
This delivery order was issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, which carries a $499.999 billion ceiling and extends through December 31, 2036. The broader PPV-G GEN V acquisition strategy, valued at $30.3 billion, establishes multiple regional prime vendor contractors to provide comprehensive pharmaceutical products including branded and generic prescription drugs, biologics, and medical consumables to support Department of Defense healthcare facilities worldwide. DMS Pharmaceutical Group's established performance on numerous delivery orders demonstrates its capability to fulfill the specialized pharmaceutical requirements of the federal military medical system.
Quick answers
Who was awarded contract SPE2DR26FSBF5?
SPE2DR26FSBF5 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 27, 2026.
How much is contract SPE2DR26FSBF5 worth?
The government has obligated $9,137 on SPE2DR26FSBF5.
Is contract SPE2DR26FSBF5 an order under another contract?
Yes. SPE2DR26FSBF5 is a delivery order under SPE2DR25D9311, an indefinite delivery contract.
Was contract SPE2DR26FSBF5 competed?
The extent of competition for SPE2DR26FSBF5 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award